Administration of Onasemnogene Abeparvovec in an Infant With Spinal Muscular Atrophy and PCR-Confirmed SARS-CoV-2 Infection
Open Access
- 19 September 2025
- journal article
- Published by Springer Nature in Cureus
- Vol. 17 (9)
Abstract
Onasemnogene abeparvovec (OA) is used to treat spinal muscular atrophy (SMA), and early treatment is critical. However, OA administration may trigger an immune response. To date, no studies have established the optimal timing for OA administration following SARS-CoV-2 infection. We report the case of an eight-month-old female infant presenting with delayed motor development who was diagnosed with SMA. OA therapy was initially prescribed but postponed because of a risk of COVID-19 exposure; the patient’s mother had recently developed COVID-19. Despite testing positive for SARS-CoV-2, the infant remained asymptomatic, and her viral load did not increase. OA was administered 19 days after the mother’s COVID-19 diagnosis. The patient did not develop COVID-19 and experienced no significant adverse effects. This case suggests that OA administration may be safe in asymptomatic SARS-CoV-2-positive patients with low viral loads, allowing timely therapy to preserve motor function. Further studies are needed to establish evidence-based guidelines for the optimal timing of OA administration.Keywords
This publication has 9 references indexed in Scilit:
- Postmarketing adverse events associated with onasemnogene abeparvovec: a real-world pharmacovigilance studyOrphanet Journal of Rare Diseases, 2025
- Acute liver failure worsened after respiratory syncytial virus infection in an infant with spinal muscular atrophy type I after receiving onasemnogene abeparvovecBrain and Development Case Reports, 2024
- Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trialNature Medicine, 2022
- Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophyMuscle & Nerve, 2021
- Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophyJournal of Hepatology, 2021
- Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1The Journal of Pediatrics, 2020
- Gene Therapy for Spinal Muscular Atrophy: Safety and Early OutcomesPediatrics, 2020
- Natural History of Asymptomatic SARS-CoV-2 InfectionNew England Journal of Medicine, 2020
- Single-Dose Gene-Replacement Therapy for Spinal Muscular AtrophyNew England Journal of Medicine, 2017